These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 7510346)

  • 1. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
    Miyamoto KK; McSherry SA; Robins SP; Besterman JM; Mohler JL
    J Urol; 1994 Apr; 151(4):909-13. PubMed ID: 7510346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer.
    Takeuchi S; Arai K; Saitoh H; Yoshida K; Miura M
    J Urol; 1996 Nov; 156(5):1691-5. PubMed ID: 8863572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The clinical usefulness of urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer].
    Takeuchi S; Saitoh H
    Nihon Rinsho; 1998 Aug; 56(8):2077-81. PubMed ID: 9750511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential changes of urinary pyridinoline and deoxypyridinoline as markers of metastatic bone tumor in patients with prostate cancer: a preliminary study.
    Samma S; Kagebayashi Y; Yasukawa M; Fukui Y; Ozono S; Hirao Y; Sato H; Okajima E
    Jpn J Clin Oncol; 1997 Feb; 27(1):26-30. PubMed ID: 9070337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer.
    Ikeda I; Miura T; Kondo I
    Br J Urol; 1996 Jan; 77(1):102-6. PubMed ID: 8653278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Assay of urinary pyridinoline and deoxypyridinoline as potential markers of the rate of bone resorption: usefulness of urinary pyridinoline and deoxypyridinoline in patients with prostate cancer with bone metastases].
    Takeuchi S; Yoshida K
    Nihon Hinyokika Gakkai Zasshi; 1994 Oct; 85(10):1521-7. PubMed ID: 7990300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis.
    Sano M; Kushida K; Takahashi M; Ohishi T; Kawana K; Okada M; Inoue T
    Br J Cancer; 1994 Oct; 70(4):701-3. PubMed ID: 7917922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone-turnover metabolites as clinical markers of bone metastasis in patients with prostatic carcinoma.
    Takeuchi S; Saitoh H
    Int J Urol; 1997 Jul; 4(4):368-73. PubMed ID: 9256326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].
    Kurokawa K; Imai K; Yamanaka H; Tomaru Y; Kitaura K
    Hinyokika Kiyo; 1985 Dec; 31(12):2119-25. PubMed ID: 2421558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum concentration of the pyridinoline crosslinked carboxyterminal telopeptide of type I collagen and urinary concentration of deoxypyridinoline as markers of bone metastases in human prostate carcinoma.
    Yoshida K; Hosoya Y; Arai K; Sumi S; Honda M
    Clin Chim Acta; 1996 Oct; 254(1):93-5. PubMed ID: 8894314
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of urinary hydroxyproline excretion as a tumor marker in diagnosis and follow-up of prostatic carcinoma.
    Unni Mooppan MM; Kim H; Wang JC; Tobin MS; Wax SH
    Prostate; 1983; 4(4):397-405. PubMed ID: 6191318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease.
    Coleman RE; Houston S; James I; Rodger A; Rubens RD; Leonard RC; Ford J
    Br J Cancer; 1992 May; 65(5):766-8. PubMed ID: 1586605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary pyridinoline and deoxypyridinoline excretion in children.
    Shaw NJ; Dutton J; Fraser WD; Smith CS
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):607-12. PubMed ID: 7634501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative urinary proteomics using stable isotope labelling by peptide dimethylation in patients with prostate cancer.
    Li C; Zang T; Wrobel K; Huang JT; Nabi G
    Anal Bioanal Chem; 2015 May; 407(12):3393-404. PubMed ID: 25724369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total and nondialyzable hydroxyproline excretion in Stage D2 prostate cancer.
    Hopkins SC; Palmieri GM; Niell HB; Moinuddin M; Soloway MS
    Cancer; 1984 Jan; 53(1):117-21. PubMed ID: 6689994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitation of urinary hydroxypyridinium cross-links from collagen by high-performance liquid chromatography.
    Kollerup G; Thamsborg G; Bhatia H; Sørensen OH
    Scand J Clin Lab Invest; 1992 Nov; 52(7):657-62. PubMed ID: 1455159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of some biochemical bone markers for the detection of bone metastases in prostate cancer.
    Westerhuis LW; Delaere KP
    Eur J Clin Chem Clin Biochem; 1997 Feb; 35(2):89-94. PubMed ID: 9056749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links.
    Uebelhart D; Schlemmer A; Johansen JS; Gineyts E; Christiansen C; Delmas PD
    J Clin Endocrinol Metab; 1991 Feb; 72(2):367-73. PubMed ID: 1991806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary bone resorption markers in patients with metabolic bone disorders.
    Ohishi T; Kushida K; Takahashi M; Kawana K; Yagi K; Kawakami K; Horiuchi K; Inoue T
    Bone; 1994; 15(1):15-20. PubMed ID: 8024845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
    Papatheofanis FJ
    J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.